← Back to Search

Doula Support Program for Advanced Cancer (Doulas-AC Trial)

N/A

Recruiting

Led By Margaret Quinn Rosenzweig, PhD

Research Sponsored by University of Pittsburgh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients diagnosed with Metastatic Breast Cancer

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, up to 6 months

Awards & highlights

Doulas-AC Trial Summary

This trial will provide support for black patients with advanced cancer in the form of a trained companion, help with exploring legacy and meaning, and practical assistance. After death, the program will also support bereaved family and friends.

Who is the study for?

This trial is for African American individuals living in or near Pittsburgh, Pennsylvania who have been diagnosed with Metastatic Breast Cancer. Participants must be able to read and understand English.Check my eligibility

What is being tested?

The 'Doulas - AC' program aims to provide a trained companion for patients with advanced cancer, focusing on dignity, legacy creation, practical support for illness needs, and bereavement support for family/friends.See study design

What are the potential side effects?

Since this intervention involves supportive care rather than medical treatment, there are no direct physical side effects; however emotional distress may arise from discussing end-of-life issues.

Doulas-AC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with breast cancer that has spread to other parts of my body.

Doulas-AC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Hospital Anxiety and Depression Scale (HADS)

Change in Interpersonal Support Evaluation List (ISEL)

Change in Patient-Reported Outcomes Measurement Information System (PROMIS-29) Questionnaire

Doulas-AC Trial Design

1Treatment groups

Experimental Treatment

Group I: DOULA -ACExperimental Treatment1 Intervention

Four hours/week of Doula and Patient engagement.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor

1,720 Previous Clinical Trials

16,342,806 Total Patients Enrolled

17 Trials studying Breast Cancer

3,381 Patients Enrolled for Breast Cancer

Margaret Quinn Rosenzweig, PhDPrincipal InvestigatorUPMC Hillman Cancer Center

Media Library

DOULA-AC 1 Clinical Trial Eligibility Overview. Trial Name: NCT05314179 — N/A

Breast Cancer Research Study Groups: DOULA -AC

Breast Cancer Clinical Trial 2023: DOULA-AC 1 Highlights & Side Effects. Trial Name: NCT05314179 — N/A

DOULA-AC 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT05314179 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are taking part in this research endeavor?

"Affirmative. According to the clinicaltrials.gov database, this medical research is actively seeking participants that meet its criteria. The initial posting was on March 13th 2022 and the most recent update occurred on August 11th 2022; currently, 5 patients are being enrolled at a single site."

Answered by AI

Is this clinical trial currently recruiting participants?

"According to clinicaltrials.gov, this medical experiment is still open for enrollment. Initially posted on March 13th 2022, the trial's details were most recently revised in August of the same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community

Margaret Quinn Rosenzweig 2022. "Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05314179.